Difference in survival and prognosis between malignant tumors of odontogenic origin
We found no difference in specific survival between the three histological groups. Although metastatic ameloblastoma was reclassified as a benign tumor by the WHO in 2017, the vital risk for patients remains consequent, and statistically similar to malignant odontogenic tumors.
Authors
- Chloé Bertolus (ORCID: https://orcid.org/0000-0002-4279-9805)
- William Pouillot
- Jean‐Philippe Foy (ORCID: https://orcid.org/0000-0002-4271-5093)
- Quentin Hennocq (ORCID: https://orcid.org/0000-0001-7882-8287)
Institutions
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre de Recherche Saint-Antoine (FR)
Publication Details
- Journal
- Journal of Stomatology Oral and Maxillofacial Surgery
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.jormas.2024.102179
- Primary Topic
- Oral and Maxillofacial Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00